Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by University of Oxford.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
GlaxoSmithKline
Cancer Research UK
Oxford University Hospitals NHS Trust
NCRI CLL Subgroup
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01171378
First received: July 22, 2010
Last updated: January 6, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2014
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)